Latest Phentermine Stories

On July 17th, 2012, the US FDA approved the new diet pill Qsymia by Vivus Inc. Qsymia is a combination of two FDA-approved drugs, phentermine and topiramate, in an extended-release formulation. Phentermine was one-half of the popular Wyeth obesity drug Fen Phen which was withdrawn from the market in 1997; it was linked with heart valve damage and primary pulmonary hypertension (PPH). Now, AttorneyOne.com, a recognized authority on law, can provide helpful, proven advice and simple...

The Website Also Recently Reached a Milestone of 200,000 Visitors Los Angeles, CA (PRWEB) July 20, 2012 Phentermine375.net, a website that helps educate its readers about the drug phentermine and its safe alternatives, has just added new video testimonials to its site. The videos were made by actual users of Phentermine 37.5, an over-the-counter product that is designed to help people lose weight. The website, which also recently reached 200,000 visitors, also offers its readers a new...

TAINAN, Taiwan, July 18, 2012 /PRNewswire-Asia/ -- ScinoPharm (TWSE:1789) announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of topiramate active pharmaceutical ingredient ("API") for VIVUS' Qsymia(TM), a new drug for the treatment of obesity approved by the United States Food and Drug Administration on July 17, 2012. Qsymia(TM) is the first FDA-approved once daily combination treatment for chronic weight management in adults who are obese...

Lawrence LeBlond for redOrbit.com - Your Universe Online The second new weight-management drug in 13 years has been approved by US regulators for use in people who are obese or overweight and have certain medical conditions. The drug, Qsymia, developed by pharmaceutical company Vivus, received Food and Drug Administration (FDA) approval just a month after another anti-obesity drug, called Belviq, was given a thumbs up. Qsymia has been approved for use in obese adults with a body mass...

MOUNTAIN VIEW, Calif., July 17, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved Qsymia(TM) (pronounced Kyoo sim ee' uh) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 or greater (obese), or 27 or greater (overweight) in the presence of at least one weight-related comorbidity, such as...

A recent study by researchers at the Beth Israel Deaconess Medical Center (BIDMC), published in the July 3 issue of Cell Metabolism, has identified the link between metabolic disease and cancer. Senior author Barbara Kahn, MD, a scientist at BIDMC and Professor of Medicine at Harvard Medical School, stated that “Maintaining normal body weight requires tight control of energy homeostasis, which necessitates a constant flow of metabolic input to the hypothalamus in the form of nutrients...

SupplementsToWeightLoss LLC (DBA: PharmaCo Labs) and also Classe Wines LLC signed a 5 years lease on a warehouse. Germantown, MD (PRWEB) June 30, 2012 SupplementsToWeightLoss LLC (DBA: PharmaCo Labs) and also Classe Wines LLC, a new and upcoming wine retailer, has today announced that they have signed a 5 years lease on a warehouse in Vienna, Virginia. The warehouse will be used to store premium wines that the company will be selling direct to consumers....

SAN DIEGO and WOODCLIFF LAKE, N.J., June 27, 2012 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BELVIQ (pronounced BEL-VEEK) as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2( )or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at...

An experimental drug helped significantly more overweight patients with diabetes shed pounds, compared with placebo, a new study finds. The results will be presented Saturday at The Endocrine Society's 94th Annual Meeting in Houston. "This new medication is promising because of the amount of weight loss it produces, the resultant improvement in important risk factors for diabetes, and, particularly in the lower dose studied, in its tolerability," said study lead author Donna H. Ryan, M.D.,...

PharmaCo Labs (SupplementsToWeightLoss LLC) today announced that their non-prescription weight loss pill, PhenObestin 37.5, has been proven to help people lose weight as quickly as prescription weight-loss drugs Phentermine and Adipex. This all-natural drug is packed with cutting edge science that helped those people lose weight with no side effects. Germantown, MD (PRWEB) May 29, 2012 More than one million people from around the world have used PhenObestin 37.5 to successfully lose...